drugset / Trial / NCT06674096
RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, single-arm, multicenter clinical study to evaluate the efficacy and safety of chidamide, rituximab combined with lenalidomide sequential immunochemotherapy in the treatment of newly diagnosed elderly double-expressor diffuse large B-cell lymphoma.
Timeline
- Start
- 2024-11-06
- Primary completion
- 2029-12-30
- Completion
- 2030-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | 10 mg | — |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | — |
| Subject | Tucidinostat | Small molecule | 20 mg | — |
| Background | Cyclophosphamide | Other / unclassified | 750 mg/m2 | — |
| Background | Doxorubicin | Other / unclassified | 35 mg/m2 | — |
| Background | Epirubicin | Small molecule | 75 mg/m2 | — |
| Background | Prednisone | Other / unclassified | 100 mg | — |
| Background | Vindesine | Small molecule | 4 mg | — |